Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347794 | 0.88 | PPARG (0.37) | PPARGKAT2BKDM4ESMN1; SMN2LMNA | |
| SCHEMBL6347799 | 0.88 | PPARG (0.37) | PPARGKAT2BKDM4ESMN1; SMN2LMNA | |
| SCHEMBL6350872 | 0.79 | KAT2B (0.38) | PPARGKAT2BKDM4ESMN1; SMN2LMNA | |
| SCHEMBL6350869 | 0.79 | KAT2B (0.38) | PPARGKAT2BKDM4ESMN1; SMN2LMNA | |
| SCHEMBL6350953 | 0.75 | KAT2B (0.35) | PPARGKAT2BKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL7094960 | 0.64 | KDM4E (0.37) | PPARGKAT2BKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL6935126 | 0.61 | KAT2B (0.34) | PPARGKAT2BKDM4ESMN1; SMN2 | |
| SCHEMBL7413865 | 0.60 | MAPT (0.34) | PPARGKAT2BKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL27579908 | 0.60 | TSHR (0.39) | KAT2BLMNAHSD17B10HTT | |
| SCHEMBL1973027 | 0.59 | PPARG (0.41) | PPARGKAT2BKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6713472-B1 | 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| EP-1211249-A1 | NOVEL THIAZINE OR PYRAZINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | PPARG 4121/4885KAT2B 3362/4885KDM4E 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.